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We studied the association between polymorph-
isms of genes coding for dopamine D2 (DRD2),
dopamine D3 (DRD3), serotonin 2a (HTR2A), and
serotonin 2c (HTR2C) receptors and Antipsycho-
tic-Induced Parkinsonism (AIP), rigidity, brady-
kinesia, and rest-tremor in African-Caribbeans
treated with antipsychotics. Polymorphisms of
DRD2 (-141CIns/Del, TaqIA, 957C>T), DRD3
(Ser9Gly), HTR2A (-1438A>G, 102T>C, His452-
Tyr), and HTR2C (-759C>T, Cys23Ser) genes were
determined according to standard protocols. The
Unified Parkinson Disease Rating Scale was used
for the measurement of AIP, rigidity, bradykine-
sia, and rest-tremor. Chi-squared or Fisher’s exact
tests were applied for the association analyses.
The t-test was applied for continuous data. Ninety
nine males and 27 females met the inclusion
criteria (Schizophr Res 1996, 19:195). In males,
but not in females, there were significant associa-
tions between -141CDel-allele carriership (DRD2)
and rigidity (Fisher’s Exact Test: P¼ 0.021) and
between 23Ser-allele carriership (HTR2C) and
bradykinesia (P¼ 0.026, v2¼5.0) or AIP (P¼ 0.008,
v2¼7.1). Rest-tremor was not associated with any
of the polymorphisms studied. Analyses of the age,
chlorpromazine equivalents, benztropine equiva-
lents, the number of patients using anticholiner-
gic medication, and the utilization patterns of the
antipsychotic medication did not show statisti-
cally significant differences between patients
with and without AIP, rigidity, bradykinesia,
rest-tremor. Conducting the analysis without
gender stratification did not affect our findings
considerably, except for the association between
bradykinesia and 23Ser-allele which failed to
reach statistical significance in the total sample
(P¼0.0646, v2¼3.41). Since AIPs subsymptoms
(rigidity, bradykinesia, and rest-tremor) may
differ pharmacogenetically, our data strongly
support symptom-specific analysis of AIP. How-
ever, further research is warranted to confirm our
findings.  2008 Wiley-Liss, Inc.
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INTRODUCTION
Antipsychotic-induced parkinsonism (AIP) is an acute
movement disorder that may appear in 15–40% of patients
within the first few weeks following the start of an anti-
psychotic and may adversely affect therapeutic compliance,
self-esteem, and quality of life [Fleischhacker et al., 1994;
Gerlach, 1999; Hofer et al., 2004; Hirose, 2006].
Several risk factors have been suggested to predispose to
AIP, such as old age, female gender, and high doses of
antipsychotics [Metzer et al., 1989; Ebadi and Srinivasan,
1995; Caligiuri et al., 1999, 2000; Jabs et al., 2003; Hirose,
2006]. However, these factors only partially explain the
variance in the occurrence of AIP and hereditary predisposi-
tion is, therefore, possible [Galdi et al., 1981; Lencer et al.,
2004].
Although the pharmacogenetics of movement disorders has
been examined extensively, many studies tend to generalize
multiple forms of drug-induced movement disorders (e.g.,
tardive dyskinesia, AIP, akathesia, dystonia) as being one
single clinical syndrome [Armstrong et al., 1997; Inada et al.,
1999; Nakazono et al., 2005; Gunes et al., 2007; Guzey et al.,
The Curac¸ao Extrapyramidal Syndromes Study VIII.
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2007]. It is however plausible that these movement disorders
do differ in their genetic liability, since each movement
disorder has a distinct clinical presentation, time to onset,
prognosis, and medical management [Trosch, 2004].
AIP may be caused by the antagonistic effects of antipsy-
chotics on nigrostriatal dopamine D2 receptors (DRD2 gene)
[Gerlach, 1999; Lidow, 2000; Reynolds, 2004], which are
modulated by serotonin 2A and 2C receptors (HTR2A and
HTR2C genes, respectively) [Lidow, 2000; Alex et al., 2005; Di
et al., 2006; Haleem, 2006].
DRD2, HTR2A, and HTR2C are therefore plausible candi-
date genes for the study of the pharmacogenetics of AIP.
Studies focusing on HTR2A and HTR2C pharmacogenetics
and AIP are currently scarce [Hamdani et al., 2005; Gunes
et al., 2007]. Furthermore, there are currently only a few
studies evaluating extensive sets of DRD2-polymorphisms in
connection with AIP [Kaiser et al., 2002; Nakazono et al., 2005;
Wu et al., 2006] and none were conducted in Negroid patients.
In contrast to akathisia [Eichhammer et al., 2000] and
tardive dyskinesia [Segman et al., 2000; Lerer et al., 2002;
Bakker et al., 2006], the pharmacogenetics of dopamine D3
receptor (DRD3 gene) and AIP is still poorly understood
[Chong et al., 2003; Gunes et al., 2007; Guzey et al., 2007].
The goal of the present study is to investigate the association
between several polymorphisms of DRD2, DRD3, HTR2A, and
HTR2C genes and AIP and three of its subsymptoms (rigidity,
bradykinesia, and rest-tremor) in African-Caribbean inpa-
tients on chronic antipsychotic treatment.
Currently, there are no studies published on the pharmaco-
genetics of AIP in Negroid populations. Since African-Car-
ibbean subjects may have ethnic roots similar to those of native
Africans [Page, 1997], the present study may also be of
relevance for other Negroid populations.
METHODS
Subjects
In this study we utilized data obtained from predominantly
African-Caribbean subjects (Negroid or Mixed), who previ-
ously had participated in an epidemiological study on anti-
psychotic-induced movement disorders [van Harten et al.,
1996]. All of the study subjects were inpatients from the Dr.
D.R. Capriles Clinic (Curac¸ao, Netherlands Antilles) and had
received nearly all of their psychiatric care from that hospital.
The study protocol was approved by the Curac¸ao institu-
tional review board. Informed consent was obtained from each
patient after full explanation of the purpose of the study and
subjects were requested to provide peripheral blood for DNA
genotyping.
Patients were included in this pharmacogentic study
regardless the presence or absence of AIP and regardless the
type or severity of their mental illness. Inclusion criteria were:
(i) absence of organic and neurological disorders that could
cause movement disorders, (ii) a history of neuroleptic use for
at least 3 months, and (iii) informed consent.
Clinical Data
AIP and its subsymptoms were measured with the motor
examination part of the Unified Parkinson Disease Rating
Scale [Martinez-Martin et al., 1994]. All of the ratings were
dichotomized in presence/absence of AIP, rigidity, rest-tremor.
Since rest-tremor and rigidity are typical of AIP, a ‘mild’
involvement on one of these items led to case definition [van
Harten et al., 1996]. If no tremor or rigidity was present, then
the cut-off point for the presence of AIP was at least one
‘moderate’ or two ‘mild’ scores on the other items [van Harten
et al., 1996].
To reduce the risk of false positives, we chose to categorize
the presence/absence of bradykinesia by the use of a
more stringent cut-off point of at least one ‘moderate’ or two
‘mild’ scores on the items speech, facial expression, hand
movements, alternating hands, foot agility, arising from chair,
posture, gait, postural stability, body bradykinesia, and
hypokinesia.
Furthermore, two junior medical doctors, who were not
aware of the existence of movement disorders in the subjects,
assessed patients’ medical files for information on the type,
dose, and duration of the antipsychotic treatment as well as
other co-medications (anticholinergics and benzodiazepines).
The dose of the antipsychotic medication was converted into
chlorpromazine equivalents and the dose of anticholinergics
into benztropine equivalents [Davis, 1976; Moleman, 1992].
DNA Genotyping
Genomic DNA was extracted from EDTA whole-blood
samples [Miller et al., 1988]. We genotyped the patients for
several polymorphisms of DRD2 (-141CIns/Del, TaqIA,
957C>T), DRD3 (Ser9Gly), HTR2A (-1438A>G, 102T>C,
His452Tyr), and HTR2C (-759C>T, Cys23Ser) genes. The
genotyping was conducted blind to the clinical status of the
patients.
Fluorogenic 50-exonuclease TaqMan1 assays were applied
for the determination of all of the polymorphisms except three
polymorphisms (102T>C, Cys23Ser, and Ser9Gly), which
were determined by standard restriction fragment length
polymorphism (RFLP) protocols [Lannfelt et al., 1992; Warren
et al., 1993; Ebstein et al., 1997]. All of the TaqMan-assays,
except one (-141C Ins/Del), were ordered from Applied
Biosystems (Nieuwerkerk aan den IJssel, the Netherlands)
as Assay-On-Demand. The -141C Ins/Del polymorphism was
performed by the use of user-designed TaqMan primers and
probes, kindly provided by Xu et al. [2004].
In relation with the 957C>T polymorphism of DRD2 gene
[Hirvonen et al., 2004], we genotyped additionally any subject
with the homozygous 957TT genotype for the 1101G>A
polymorphism of DRD2, since it has been reported that the
effects of the 957T-allele are annulated in presence of the
1101A-allele [Duan et al., 2003]. The genotyping of 1101G>A
polymorphism was conducted by a PCR-RFLP protocol, as
kindly provided by Hirvonen et al. [2004].
Statistics
The associations between allele-positivity (allele carriership
status) and AIP, rigidity, bradykinesia, and rest-tremor were
analyzed by the use of Chi-squared or Fisher’s exact tests (2 2
contingency tables). Chi-squared or Fisher’s exact tests were
also applied for the analyses of other dichotomous variables
(e.g., anticholinergics and polypharmacy use).
Logistic regression was applied for the calculation of the
Odds Ratio (OR) and adjusted OR (OR_adj) for polymor-
phisms with a significant association. For analyses of age,
chlorpromazine- and benztropine equivalents the t-test
was applied. The analyses were conducted twice; with and
without gender-stratification. P values <0.050 were regarded
as significant. In our study we endeavored to replicate data
from previous studies (some of which not reporting an
association) rather than to explore new genetic targets. Since
our approach is hypothesis driven, we did not correct for
multiple testing.
Departure from Hardy–Weinberg Equilibrium was calcu-
lated for all polymorphisms except those of the X-chromosomal
HTR2C gene. An online tool was applied for the chi-square
goodness-of-fit test (http://www.kursus.kvl.dk/shares/vetgen/
_popgen/genetik/applets/kitest.htm; accessed October 28th 2007).
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RESULTS
Demographic and Clinical
Features of the Subjects
One hundred twenty six African-Caribbean subjects
(99 males and 27 females) met the inclusion criteria. Table I
presents the distribution (mean standard deviation) of age
(years), DSM-III-R diagnosis, ethnicity, polypharmacy (num-
ber of patients using no, single, or multiple antipsychotics
simultaneously), lifetime exposure to antipsychotics (kilogram
chlorpromazine equivalents), age on first neuroleptic use
(years), daily dose of antipsychotics (mg/day chlorpromazine
equivalents) and anticholinergics (mg/day benztropine equiv-
alents) as well as the number and percentage of subjects using
anticholinergic medication. Table I also presents the number of
cases of AIP, rigidity, bradykinesia, and rest-tremor in the




None of the polymorphisms tested deviated from the HWE
(Table II). For some polymorphisms we failed to genotype 1
(DRD2 -141CIns/Del, HTR2A His452Tyr, and -1438G>A) or 2
(HTR2C -759C>T) DNA samples, due to insufficient DNA
quality or quantity.
Of the five subjects with the homozygous 957TT genotype
(DRD2 957C>T polymorphism), none had the 1101AA
genotype (DRD2 1101G>A).
Since we found in the total sample that for some poly-
morphisms the frequency of homozygote subjects could be as
low as 3.2%, and becomes even lower after stratification by
gender, we chose to characterize subjects either as carriers or
non-carriers of an allele, if they were heterozygote, hemi-
zygote, or homozygote for that particular allele. However, it
should be noted that this conservative approach does not
reflect any specific hypothesis regarding the mode of inher-
itance (i.e., we do not suggest a dominant inheritance mode).
Genotype and allele-carriership frequencies are shown in
Table II.
Comparison of Allele-Carriership
Frequencies in Cases and Non-Cases
AIP. As shown in Table III, w2 test in the total sample
indicates significant associations between AIP and HTR2C
23Ser-allele carriership (w2¼ 5.35, P¼0.021). All other poly-
morphisms were not significantly associated with AIP (data
not shown).
The frequency of AIP in patients carrying the 23Ser-allele of
HTR2C gene is 1.7 times higher than in non-carriers (50.0 vs.
29.5%). Furthermore, the OR for having AIP in 23Ser-allele
carriers was significant (OR¼ 2.39, P¼0.022). Adjustment of
the OR for age, chlorpromazine- and benztropine equivalents
daily used, did not affect the results adversely (OR_adj¼ 2.61,
P¼0.017).
After gender stratification, the association between carrier-
ship of 23Ser-allele and AIP remained significant in males
(w2¼ 7.05, P¼0.008), but not in females (Fisher’s Exact Test:
TABLE I. The Distribution of Age, Diagnosis (DSM-III-R), Ethnicity, Polypharmacy, Daily Use of Antipsychotics (mg/Day
Chlorpromazine Equivalents, CPZeq) on the Day of Assessment of the UPDRS, Lifetime Exposure to Antipsychotics (kg CPZeq), Age
First Neurolerptic use (Years), Daily use of Anticholinergics (mg/Day Benztropine Equivalents, BNZeq) on the Day of Assessment of the
UPDRS, and the Number (n) and Percentage (%) of Subjects Using Anticholinergics or Benzodiazepines as well as AIP, Rigidity,
Bradykinesia, and Rest-Tremor Cases
All (126) Male (99) Female (27)
Age (years) 49.213.4 47.5 13.0 55.4 13.3
Diagnosesa,b, n (%)
Schizophreniac 88 (80.7) — —




Negroid or mixed 108 (95.6) — —
Caucasian 3 (2.7)
Other 2 (1.8)
Polypharmacy, number of patients using




Daily use of antipsychotics (mg
CPZeq/day)
686.0740.6 692.4 676.8 662.5 953.8
Lifetime exposure to antipsychotics
(kg CPZeq)e
3.93.2 3.9 3.2 4.0 3.2
Age first neurolerptic use (years)e 29.810.9 28.6 10.2 33.7 12.6
Daily use of anticholinergics (mg
BNZeq/day)
1.42.1 1.6 2.2 0.7 1.4
Patients on anticholinergics, N (%) 49 (38.9%) 42 (33.3%) 7 (5.6%)
Patients on benzodiazepines, N (%) 28 (22.2%) 23 (23.2%) 5 (18.5%)
AIP present, n (%) 47 (37.3) 35 (35.4) 12 (44.4)
RIG present, n (%) 14 (11.1) 11 (11.1) 3 (11.1)
TREM present, n (%) 21 (16.6) 18 (18.2) 3 (11.1)
BRAD present, n (%) 33 (26.2) 23 (23.2) 10 (37.0)
aData from 109 patients.
bA patient can have several diagnosis, thus the total number exceeds 100%.
cIncludes 295.1, 295.2, 295.3, 295.4, 295.6, 296.7, 295.9.
dData from 113 patients.
eData from 93 patients (72 malesþ 21 females).
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P¼ 1.000). The OR and OR_adj were also significant in males
(OR¼ 3.30, P¼0.009 and OR_adj¼ 3.91, P¼0.005), but not
females (OR¼ 0.73, P¼ 0.707 and OR_adj¼ 0.75, P¼ 0.763).
Rigidity. As shown in Table III, w2 test in the total sample
indicates significant associations between rigidity and DRD2 -
141CDel-allele carriership (w2¼ 8.02, P¼0.005). All other
polymorphisms were not significantly associated with rigidity
(data not shown). The frequency of rigidity in patients carrying
the -141CDel allele of DRD2 gene was 9.5 times higher,
compared to non-carriers (18.1 vs. 1.9%). The OR and OR_adj
for having rigidity in -141CDel carriers was significant
(OR¼ 11.46, P¼0.021 and OR_adj¼ 13.21, P¼0.018).
After gender stratification, Fisher’s Exact Test indicated
a significant association between carriership of -141CDel-
allele and rigidity in males (P¼0.021), but not in females
(P¼ 0.262).
The OR and OR_adj were also significant in males
(OR¼ 9.13, P¼0.039 and OR_adj¼ 8.98, P¼0.049), but not
females (OR, OR_adj, and P values not rateable).
Bradykinesia. As shown in Table III, w2 test in the total
sample indicated a non-significant trend towards an associa-
tions between bradykinesia and HTR2C 23Ser-allele carrier-
ship (w2¼ 3.41, P¼ 0.065, OR¼ 2.13, P¼ 0.067 and OR_adj
2.27, P¼ 0.054). In the total sample, the frequency of
bradykinesia in 23Ser-allele carriers was 1.7 times higher
than in non-carriers (35.4 vs. 20.5%). All other polymorphisms
were not significantly associated with bradykinesia (data not
shown). After gender stratification, the association between
carriership of 23Ser-allele and bradykinesia became signifi-
cant in males (w2¼ 5.0, P¼0.026, OR¼ 2.95, P¼ 0.029 and
OR_adj¼ 3.40, P¼0.018), but not in females (Fisher’s Exact
Test: P¼ 0.415, OR¼ 0.46, P¼ 0.370 and OR_adj¼ 0.44,
P¼ 0.380).
Rest-tremor. Rest-tremor was not associated with any of
the polymorphisms studied, as determined by w2 test, Fisher’s
Exact Test, and logistic regression (data not shown).
Comparison of Age and the use of Antipsychotics,
Anticholinergics and Benzodiazepines
Mean age (years), mean chlorpromazine and benztropine
equivalents (mg/day), and the proportion of patients using
anticholinergic medication did not differ significantly neither
between subjects with and without AIP, rigidity, bradykinesia,
and tremor nor between carriers and non-carriers of 23Ser
(HTR2C) and -141CDel (DRD2) alleles (data not shown).
Furthermore, the frequency of patients using benzodiazepines
did not differ significantly between cases (18.2%) and non-
cases (23.7%) of bradykinesia (w2¼ 0.42, P¼ 0.516) or between
carriers (18.8%) and non-carriers (24.4%) of 23Ser allele of the
Cys23Ser polymorphism (w2¼ 0.54, P¼ 0.462).












































Cys23/Cys23 61.9 (78) — Carriers of the 23Ser allele 38.1 (48) 29.3 (29) 70.4 (19)
Cys23/Ser23 11.1 (14)
Ser23/Ser23 27.0 (34)
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Gender stratification did not alter any of the abovemen-
tioned findings (data not shown), except for the male DRD2 -
141CDel allele non-carriers who had a significantly (P¼0.014)
higher mean chlorpromazine equivalents than male carriers of
that allele (892 vs. 539 mg/day, respectively).Furthermore, we
analyzed the type of the antipsychotics used. Most of the
patients (n¼ 114) used antipsychotics on the day of examina-
tion. Of whom, 7 patients were using an atypical antipsychotic
as monotherapy (risperidone in all cases), and 1 patient was
using risperidone in combination with a classical neuroleptic.
On the day of examination 75% of the users of antipsychotics
were on monotherapy and 25% used 2 or more antipsychotics
simultaneously. Of the patients using two or more antipsy-
chotics, only two were using three antipsychotics simulta-
neously. To test whether polypharmacy has affected our
finding, we applied 2 2 contingency tables to compare
subjects without prescribed antipyschotics on the day of
UPDRS-assessment versus those using at least 1 antipsychotic
as well as those using 2 or 3 antipsychotics versus those with 1
or none antipsychotics in relation to AIP, rigidity, tremor,
bradykinesia, and carriership of the Cys23Ser and -141C Ins/
Del polymorphisms (HTR2C and DRD2 genes, respectively). In
all of the comparisons made, we do not find any significant
difference in the utilization patterns of the antipsychotic
medication (data not shown).
DISCUSSION
The present study suggests that rigidity, bradykinesia, and
rest-tremor may have different genetic vulnerability, because
these neurological phenomena did differ in their association
with polymorphisms of HTR2A, HTR2C, DRD2, and DRD3
genes. We found for example in males that the Cys23Ser
(HTR2C) and the -141CIns/Del (DRD2) polymorphisms are
associated with bradykinesia, AIP and rigidity, respectively,
but none is associated with rest-tremor. This symptom-specific
relationship may probably reflect a difference in the genetic
predisposition for the different parkinsonian phenomena. Of
the published pharmacogenetic studies dealing with AIP as a
discrete clinical entity only few [Mihara et al., 2000, 2001]
dissect AIP into its subsymptoms (e.g., rigidity, tremor,
bradykinesia, etc.).
In fact, it is plausible that some of these symptoms have
distinct neurological circuits, etiology, pathophysiology, and/
TABLE III. Cross Tabulation of Antipsychotic-Induced Parkinsonism (AIP), Rigidity, and Bradykinesia in Relation With 23Ser
(HTR2C), -141CDel (DRD2), and 23Ser (HTR2C) Allele Carriership, Respectively
Genetic variation Significance
Total sample (n¼ 126) AIP¼no n (%) AIP¼ yes n (%)
23Ser non-carriership 55 (70.5) 23 (29.5) w2¼5.35, P¼0.021; OR¼2.39 [CI: 1.13–5.04], P¼0.022;
OR_adj¼2.61 [CI: 1.19–5.74], P¼0.017;
23Ser carriership 24 (50.0) 24 (50.0)
Males (n¼99)
23Ser non-carriership 51 (72.9) 19 (27.1) w2¼7.05, P¼0.008; OR¼3.30 [CI: 1.34–8.14], P¼0.009;
OR_adj¼3.91 [CI: 1.50–10.23], P¼0.005;
23Ser carriership 13 (44.8) 16 (55.2)
Females (n¼ 27)
23Ser non-carriership 4 (50.0) 4 (50.0) Fisher’s exact test: P¼ 1.000; OR¼ 0.73 [CI: 0.14–3.82],
P¼0.707; OR_adj¼ 0.75 [CI:0.12–4.87], P¼ 0.763;
23Ser carriership 11 (57.9) 8 (42.1)
Rigidity¼no n (%) Rigidity¼ yes n (%)
Total sample (n¼ 125)
-141CDel non-carriership 52 (98.1) 1 (1.9) w2¼8.02, P¼0.005; OR¼11.46 [CI: 1.45–90.60], P¼0.021;
OR_adj¼13.21 [CI: 1.57–111.07], P¼0.018;
-141CDel carriership 59 (81.9) 13 (18.1)
Males (n¼99)
-141CDel non-carriership 42 (97.7) 1 (2.3) Fisher’s exact test: P¼0.021; OR¼9.13, [CI: 1.12–74.36];
P¼0.039 OR_adj¼8.98 [CI: 1.01–79.52], P¼0.049;
-141CDel carriership 46 (82.14) 10 (17.9)
Females (n¼ 26)
-141CDel non-carriership 10 (100.0) 0 (0.0) Fisher’s exact test: P¼ 0.262; infinite OR, OR_adj, and P
values due to many zero values
-141CDel carriership 13 (81.2) 3 (18.8)
Bradykinesia¼no n (%) Bradykinesia¼ yes n (%)
Total sample (n¼ 126)
23Ser non-carriership 62 (79.5) 16 (20.5) w2¼ 3.41, P¼0.065; OR¼ 2.13 [CI: 0.95–4.77], P¼ 0.067;
OR_adj¼ 2.27 [CI: 0.99–5.21], P¼ 0.054;
23Ser carriership 31 (64.6) 17 (35.4)
Males (n¼99)
23Ser non-carriership 58 (82.9) 12 (17.1) w2¼5.0, P¼0.026; OR¼2.95 [CI: 1.12–7.82], P¼0.029;
OR_adj¼3.40 [CI: 1.23–9.41], P¼0.018;
23Ser carriership 18 (62.1) 11 (37.9)
Females (n¼ 27)
23Ser non-carriership 4 (50.0) 4 (50.0) Fisher’s exact test: P¼ 0.415; OR¼ 0.46 [CI: 0.09–2.50],
P¼0.370; OR_adj¼ 0.44 [CI: 0.07–2.79], P¼0.380;
23Ser carriership 13 (68.4) 6 (31.6)
Significant results are printed in bold. CI, 95% confidence interval; n, number of subjects; %, percentage within carriership status; OR, odds ratio; OR_adj,
odds ratio adjusted for age, dose of the antipsychotic medication, and dose of anticholinergic medication.
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or genetic liability. For example it has been shown that
stimulation of certain brain regions in patients with Parkinson
Disease (which has symptoms similar to those of AIP) may lead
to differential effects on rigidity and tremor [Bejjani et al.,
1997; Krack et al., 1998; Gross et al., 1999]. Furthermore, the
symptomatic treatment of the Parkinson Disease is symptom-
dependent [Siemers, 1992; Koller, 1992]. Anticholinergic
preparations for instance are generally considered effective
for tremor and rigidity but not for bradykinesia, which is better
treated with Levodopa.
Recent work [Lerer et al., 2005] on another movement
disorder (tardive dyskinesia) supports this approach too,
because two subclasses of tardive dyskinesia (orofacial- and
limbotruncal tardive dyskinesias) do differ in their association
with particular genetic markers.
Moreover, examination of the published papers in this field
reveals that the majority of the pharmacogenetic papers do not
even assess AIP as a discrete clinical syndrome, but rather pool
this syndrome with other antipsychotic-induced movement
disorders. Although there is some overlap between the differ-
ent types of antipsychotic-induced movement disorders (tar-
dive dyskinesia, AIP, akathisia, and dystonia) [van Harten
et al., 1997], these different types of movement disorders do
differ considerably from each other in many points [Trosch,
2004]. Pooling these different types of movement disorders
may, therefore, be detrimental for the analyses.
The significant associations observed in this study were
exhibited in males, but not in females. Although gender-
related effects can not be excluded, the lack of associations in
the female sample is probably due to the small number of
female subjects included in our study (i.e., insufficient power).
In the current study we find a significant association
between bradykinesia or AIP and HTR2C Cys23Ser poly-
morphism, which—although debated [Jonsson et al., 2004;
Fentress et al., 2005]—has been suggested to be functional
[Okada et al., 2004]. This finding is completely in line with the
findings of the only other published study [Gunes et al., 2007].
In our sample, the minor-allele frequency of the Cys23Ser
polymorphism (Ser allele) was 0.26, which is higher than that
of Asians (0.03) and Europeans (0.16) (www.genecards.org;
accessed October 28th 2007).
In relation with HTR2A gene, we find no evidence for any
association with its polymorphisms (-1438A>G, 102T>C,
and His452Tyr). This lack of association between AIP and
-1438A>G polymorphism has also been reported by Hamdani
et al. [2005]. Gunes et al. [2007] reported a higher 102C allele
frequency in 25 Estonian patients with either parkinsonism
(n¼ 23) or akathisia (n¼ 2). However, the utilization of allele
frequencies, instead of allele-positivity (as in our study), may
has led to biased conclusions as discussed by Ohashi and
Tokunaga [1999] and Ohashi et al. [2001]. Indeed, when Gunes
et al. [2007] compared the median SAS scores between the
three genotype classes of 102T>C polymorphism, there was no
significant difference observed. Furthermore, Gunes et al.
[2007] reported that the frequency of the 452Tyr allele
(His452Tyr polymorphism) was not significantly different in
cases as compared to non-cases. Taken all together, currently,
there is no strong evidence for an association between these
polymorphisms and AIP.
Notably, our data do not support the view that genetic
variations of the DRD2 gene significantly predispose to AIP—
when measured as a total syndrome—and hence do replicate
findings of three other studies in German [Kaiser et al., 2002]
and Asian [Chong et al., 2003; Wu et al., 2006] patients,
respectively. However, we do find a significant association
between rigidity and the DRD2 promoter variant -141CIns/
Del, which—although debated [Pohjalainen et al., 1999;
Ritchie and Noble, 2003]—has been suggested to be functional
[Arinami et al., 1997; Jonsson et al., 1999] or in linkage
disequilibrium with another functional polymorphism [Duan
et al., 2003]. This relationship with rigidity was not reported by
the only co-existing study on 52 Japanese subjects [Mihara
et al., 2001], who are ethnically different from African-
Caribbeans. The frequency of the minor allele of this poly-
morphism (the Del allele) was 0.35 in our sample, which is 2–
3 times higher than that of Asians (0.16) and Europeans (0.11)
(SZGene, www.schizophreniaforum.org; accessed October
28th 2007).
Two other studies did report an association between the
-141CIns/Del polymorphism and extrapyramidal symptoms
[Inada et al., 1999; Nakazono et al., 2005]. However, these
studies are probably biased due to pooling of parkinsonism
with other types of movement disorder (akathisia, dyskinesia,
and dystonia).
We chose DRD3 gene because many studies have shown that
it may be associated with tardive dyskinesia [Lerer et al., 2002;
Bakker et al., 2006]. Our study however provides no evidence
for a relationship between this polymorphism and symptoms of
AIP, which is in agreement with the literature [Chong et al.,
2003; Gunes et al., 2007; Guzey et al., 2007]. This finding
suggests that the genetic vulnerability for tardive dyskinesia
may differ from that for antipsychotic-induced parkinsonism.
A limitation of our study is that we did not correct for
variation in the psychopathology of the patients. However, our
study sample can be considered as homogenous, since the
majority of the patients was of African-Caribbean origin and
had schizophrenia. Furthermore, the presence of organic and
neurological disorders that may cause movement disorders
was a stringent exclusion criterion. Since we followed our
patients for 10 years [van Harten et al., 2006], neurological
diseases such as Morbus Parkinson would have been detected
[Hausner, 1983].
Factors other than genetic polymophisms (i.e., confounders)
may also cause the parkinsonian symptoms. Tremor for
example may be an essential tremor or may be induced by
other drugs (such as antidepressants or antiepileptics).
However, these tremors are predominantly postural, whereas
we examined our patients for rest tremor, which is more
specifically related to antipsychotics and AIP.
Furthermore, we compared the means of age, chlorproma-
zine and benztropine equivalents as well as the number of
patients using anticholinergic medication and the number of
antipsychotics used per patient (polypharmacy) in cases and
non-cases of AIP, rigidity, bradykinesia, and rest-tremor and
in carriers and non-carriers of 23Ser (HTR2C) and -141CDel
(DRD2) alleles. Overall there were no statistically significant
differences between the compared groups, except for male
carriers of the -141CDel allele (DRD2) who had significantly
lower mean chlorpromazine equivalents than non-carrier male
patients (a fact which may only reinforce our findings). Of note,
the majority of the patients were using typical (first gener-
ation) antipsychotics. There is, therefore, no indication for
biased findings due to difference in the utilization patterns of
antipsychotics.
Bradykinesia might be caused by psychiatric symptoms or
sedation. We therefore chose a more stringent cut-off point (see
Methods Section). Additionally, we evaluated the utilization of
benzodiazepines in our sample and found that the number of
patients using benzodiazepines does not differ significantly
between bradykinesia cases and non-cases or between carriers
and non-carriers of 23Ser allele (HTR2C).Another limitation of
the present study is that the UPDRS is not developed
specifically to measure AIP. However, the UPDRS is a reliable
and a valid instrument that has been extensively tested and
used for Parkinson’s disease. Since the phenomenology of
Morbus Parkinson is not essentially different from the
phenomenology of drug-induced parkinsonism, we assume
that the UPDRS is able to measure AIP. In fact, several studies
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have utilized the UPDRS for the measurement of drug-induced
parkinsonism [van Harten et al., 1996, 2006; Lera and
Zirulnik, 1999; Hassin-Baer et al., 2001; Jamora et al., 2007].
Additionally, the UPDRS is far more comprehensive and
balanced than the often used Simpson-Angus Scale (SAS),
which has been criticized for overemphasizing rigidity items
(6 out 10 items measure rigidity, while only 1 item measures
tremor) as well as other shortcomings recently highlighted by
Loonen and van Praag [2007].
In our study we have endeavored to replicate data from
previous studies rather than to explore new genetic targets.
Since our approach is hypothesis driven, we did not correct for
multiple testing. In fact, the issue of correction for multiple
testing is a subject of ongoing debate. The European Society of
Human Genetics states that ‘‘How to correct for this [multiple
testing for genetic association] is still under debate. The
Bonferroni correction could overcorrect for the inflated false-
positive rate, and as a consequence, valid information would be
discarded . . .What is even more concerning than the incidence
of false-positives is the potential lack of detecting genuine
effects’’ (http://www.eshg.org; accessed November 11th 2007).
To give an example, since we tried to replicate a number of
studies simultaneously in the same sample, correction for
multiple testing would obviously lower the chance of statisti-
cally significant confirmation of studies investigating only 1
SNP.
CONCLUSIONS
The present study does support an association between the
-141CIns/Del (DRD2) polymorphism and rigidity and between
the Cys23Ser (HTR2C) polymorphism and AIP or bradykinesia
in African-Caribbeans. However, this study does not provide
evidence for a genetic association between rest-tremor and any
of the polymorphisms studied.
Since our data suggest that AIP and its more specific
subsymptoms rigidity, rest-tremor, and bradykinesia may
differ pharmacogenetically, our data strongly support symp-
tom-specific approach in contrast to recent pharmacogenetic
studies that pool even the different extrapyramidal symptoms
in their analyses. Further research is however warranted to
confirm our findings.
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